deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT02336048

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

A Multicenter, Double-Blind, Randomized, and Placebo-controlled Phase Ib Study Evaluating the Safety of Adding Tocilizumab to Standard Premedications Prior to Administration of Obinutuzumab in Combination With Chlorambucil in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia and Comorbidities

Sponsor: Hoffmann-La Roche

Updated 15 times since 2017 Last updated: Apr 6, 2021 Started: Jun 26, 2015 Primary completion: Sep 21, 2018 Completion: Sep 21, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR.

Listed as NCT02336048, this PHASE1 trial focuses on B-Cell Chronic Lymphocytic Leukemia and remains terminated or withdrawn. Sponsored by Hoffmann-La Roche, it has been updated 15 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Oct 2020 · 11 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. May 2021 — Dec 2021 [monthly]

    Terminated PHASE1

    Status: CompletedTerminated

Show 10 earlier versions
  1. Jan 2021 — May 2021 [monthly]

    Completed PHASE1

  2. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: TerminatedCompleted

  3. Nov 2019 — Oct 2020 [monthly]

    Terminated PHASE1

    Status: CompletedTerminated

  4. Nov 2018 — Nov 2019 [monthly]

    Completed PHASE1

    Status: Active Not RecruitingCompleted

  5. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: RecruitingActive Not Recruiting

  6. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  8. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  9. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .